Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Lymphoma 341Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Leukemia, Lymphocytic, Chronic, B-Cell 249Lymphoma, Non-Hodgkin 227Lymphoma, Large B-Cell, Diffuse 208Lymphoma, Follicular 201Burkitt Lymphoma 183Lymphoma, Mantle-Cell 166Leukemia 148Lymphoma, B-Cell, Marginal Zone 145Hodgkin Disease 141Lymphoma, Large-Cell, Immunoblastic 124Lymphoma, T-Cell, Cutaneous 108Leukemia, Myeloid, Acute 106Multiple Myeloma 97Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 96Lymphoma, Large-Cell, Anaplastic 96Mycosis Fungoides 90Sezary Syndrome 87Waldenstrom Macroglobulinemia 84Immunoblastic Lymphadenopathy 73Neoplasms 60Myelodysplastic Syndromes 59Blast Crisis 57Intraocular Lymphoma 49Hematologic Neoplasms 46Congenital Abnormalities 45Myeloproliferative Disorders 44Dendritic Cell Sarcoma, Interdigitating 44Leukemia, Myelomonocytic, Chronic 42

Interventions

talimogene laherparepvec 1Specimen Handling 1Nivolumab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Paget Disease, Extramammary × Lymphoid × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡